The Wegovy Pill vs Injection: Cost and Value Compared
The oral Wegovy tablet (oral semaglutide 25mg) is available from about $149/month for qualifying patients, while injectable Wegovy self-pay runs ~$349/month via NovoCare. The pill suits needle-averse patients; the injection has the deeper evidence base.
- Oral Wegovy from ~$149/mo (qualifying patients); injectable ~$349/mo self-pay.
- Oral semaglutide requires a much higher dose due to poor absorption.
- Both are FDA-approved semaglutide; the injection has more weight-loss trial data.
- Choice depends on cost, needle preference, and clinical fit.
The cost comparison
The oral Wegovy tablet, containing oral semaglutide, is available from about $149 per month for qualifying patients through NovoCare, making it one of the cheaper FDA-approved semaglutide routes. Injectable Wegovy self-pay runs about $349 per month through the same program.
For an uninsured patient who wants an FDA-approved product, the oral tablet can be substantially cheaper than the injection while still delivering an approved medication rather than a compounded one.
Insured pricing depends on your plan and can be lower than either cash figure.
Why the pill needs a higher dose
Oral semaglutide is poorly absorbed through the gut, so the oral products use a much higher dose than the injection to achieve comparable blood levels. The oral weight-management dose is 25mg daily, versus 2.4mg weekly for the injection.
This absorption challenge is also why the oral tablet must be taken on an empty stomach with specific timing rules. Following the instructions matters for the drug to work.
It is a genuinely different pharmacokinetic situation, not simply the same drug in pill form.
| Attribute | Oral tablet | Injection |
|---|---|---|
| Dose | 25mg daily | 2.4mg weekly |
| Self-pay/mo | from $149 | ~$349 |
| Administration | Pill, empty stomach | Weekly injection |
| Evidence | OASIS trials | STEP, SELECT |
The evidence base
Injectable semaglutide has the deeper weight-loss trial base, including STEP and SELECT. Oral semaglutide for weight management is supported by its own trials (the OASIS programme), which demonstrated meaningful weight loss, leading to FDA approval of the oral weight-management product.
Both are FDA-approved semaglutide, so both carry the assurance of manufacturing standards and regulatory review that compounded products lack.
The injection's evidence base is larger simply because it came first; the oral product's approval reflects its own successful trials.
Who each suits
The pill suits patients who are needle-averse, want an FDA-approved product, and can follow the empty-stomach timing rules. The injection suits patients comfortable with a weekly shot who want the deepest evidence base and, for some, the cardiovascular indication.
Cost can tip the decision for uninsured patients: the oral tablet's ~$149 starting price is attractive. But the timing rules and daily dosing are real considerations.
Compounded semaglutide is a separate, non-approved category that competes on price but not on regulatory standing.
| If you... | Consider |
|---|---|
| Dislike needles | Oral tablet |
| Want deepest evidence / CV indication | Injection |
| Want lowest approved-product cost | Oral tablet |
The bottom line
The oral Wegovy tablet offers an FDA-approved semaglutide from about $149 per month for qualifying patients, cheaper than the ~$349 injectable self-pay, at the cost of daily dosing and strict timing rules.
Both are approved products with real trial evidence. The choice comes down to cost, needle preference, dosing convenience, and clinical fit, which your clinician can help weigh.
Either approved route avoids the FDA-approval gap of compounded semaglutide.
Frequently asked questions
Is the Wegovy pill cheaper than the injection?
For qualifying self-pay patients, yes: the oral tablet starts around $149/month versus ~$349 for the injection via NovoCare.
Why does the pill use a much higher dose?
Oral semaglutide is poorly absorbed through the gut, so it needs 25mg daily to reach effective levels, versus 2.4mg weekly for the injection.
Are both FDA-approved?
Yes, both are FDA-approved semaglutide products with their own trial evidence. Compounded semaglutide is a separate, non-approved category.
Do I have to take the pill a certain way?
Yes, on an empty stomach with specific timing, because absorption is limited. Following the instructions matters for it to work.
Sources
- FDA — drug labels and compounding status (Drugs@FDA, fda.gov/drugs/human-drug-compounding).
- Provider pricing and manufacturer sources, September 2026.
- Forbes Health, U.S. News reviews, July 2026.
- Evidence policy: evidence policy.
The numbers behind this page
The semaglutide price range, stated precisely
Standard-dose compounded semaglutide runs $119 to $299 a month across the 12 programmes we can price, with a median of $198. The spread between cheapest and dearest is $166 a month, or $1,992 across a year, for a molecule that is chemically identical in every case.
The cheapest verified figure is NexLife at $119 on its 12-month plan; Oak Longevity follows at $133. Half the market sits below $198 and half above it, which makes the median a more useful reference point than the cheapest figure when judging whether a quote is reasonable.
2 programmes additionally advertise a semaglutide microdose, the cheapest at $145 a month. Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
How semaglutide is kept current
The semaglutide figures on this page span $119 to $299 a month across 12 programmes. Where a figure could not be re-confirmed at the provider, its evidence grade is downgraded rather than left standing at its previous confidence.
Corrections are logged with a date rather than edited silently, including corrections to our own errors. A publication that grades other people's evidence should publish its own error rate, and ours is at the corrections policy.
No provider pays for placement, position or inclusion here. Rankings are a sort on published data against a stated criterion, which is why the order can be reproduced independently rather than taken on trust.
Reading the price against the market
Why the spread is this wide
Standard-dose semaglutide spans $119 to $299 a month across 12 programmes we can price, a spread of $180.
The molecule is chemically identical across every programme in the range. The $166 a month between the cheapest and dearest semaglutide programme is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Why the spread is this wide
Standard-dose semaglutide spans $119 to $299 a month across 12 programmes we can price, a spread of $180.
The molecule is chemically identical across every programme in the range. The $166 a month between the cheapest and dearest semaglutide programme is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Questions this page answers
Why is microdosed semaglutide cheaper?
Because it is less medicine. 2 programmes advertise a semaglutide microdose, the cheapest at $145 a month. A microdose sits below every dose studied in the pivotal trials, so it is not a cheaper route to the result those trials measured.
What is the cheapest compounded semaglutide?
NexLife at $119 a month at a standard therapeutic dose on the 12-month plan ($1,428 total), captured 2026-09-04. 3-month $132; 6-month $125; month-to-month $139. No membership fee, flat at every covered dose. Verified. The next-cheapest is Oak Longevity at $133 (flat, no subscription; not available in California; Provider Reported).
What does compounded semaglutide normally cost?
$119 to $299 a month across 12 programmes, with a median of $198. Half the market sits either side of that median, which makes it a better reference than the cheapest figure when judging a quote.
Does compounded semaglutide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.